Novo Nordisk's new CEO is set to face intense investor scrutiny this week as the Wegovy-maker shakes up its board and pursues ...

November, single-dose vials of the popular weight-loss jab—Zepbound (tirzepatide)—will be available to buy from Walmart pharmacies across the U.S., thanks to a new collaboration between the retailer ...

Metsera's shareholders are scheduled to meet on November 13 to decide on Novo Nordisk's offer of around $8.5 billion, while ...

The partnership between LillyDirect and Walmart allows patients to pick up Zepbound at Walmart pharmacies at the same ...

A rendering of Eli Lilly's planned plant expansion in Pleasant Prairie. The company is preparing for a next phase on a site ...

Pfizer filed an antitrust lawsuit on Monday accusing Danish drugmaker Novo Nordisk of structuring its $9 billion bid for ...

The GLP-1 drug market has surged dramatically in the past four years, driven by soaring demand for weight-loss treatments ...

Determining the type of diabetes a patient has at diagnosis can be challenging, and health care professionals should focus on each patient’s clinical condition when determining initial treatment, ...

The healthcare industry has proven to be a resilient place for investors to put cash to work over the years. If you are ...

Tirzepatide, a medication sold under the names Mounjaro for diabetes and Zepbound for weight loss, has shown impressive results in helping people avoid developing diabetes. A new study found that it ...

Biotech Viking Therapeutics has gained prominence over the past two years, but it could have plenty of upside left.

Novo Nordisk made a surprise bid for Metsera to boost its weight-loss market lead, trading at just 12x 2026 EPS. Read why NVO ...